Intra-Cellular Therapies, Inc.
ITCI
Clasificación en acciones
#1691
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on... Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on creating innovative treatments for conditions affecting the brain and nervous system. The company achieves this by targeting the intricate cellular communication pathways within the central nervous system, primarily operating in the United States. Its commercialized product is CAPLYTA, an approved therapy for schizophrenia in adult patients. Furthermore, the company maintains a robust development pipeline, including lumateperone, which is undergoing late-stage (Phase III) clinical trials for bipolar depression and is also being investigated for autism spectrum disorder and various sleep disturbances associated with neuropsychiatric and neurological illnesses. Other key drug candidates in its pipeline include Lenrispodun (ITI-214), aimed at treating Parkinson's disease and heart failure; ITI-1284-ODT-SL, designed to address neuropsychiatric disorders and behavioral challenges in dementia; and ITI-333, intended for substance use disorders, pain management, and co-occurring psychiatric conditions like depression and anxiety. Established in 2002, Intra-Cellular Therapies, Inc. has its headquarters situated in New York, New York.
Precio por acción
$131.87
Última sincronización: 2025-04-02
Capitalización bursátil
$12.68B
Cambio (1 día)
0.00%
Cambio (1 año)
0.00%
País
US
Comercio Intra-Cellular Therapies, Inc. (ITCI)
Categoría
Healthcare
Número de acciones en circulación de Intra-Cellular Therapies, Inc. (ITCI)
Número de acciones en circulación al December 2024: 103.13M
Según los últimos informes financieros y el precio de las acciones de Intra-Cellular Therapies, Inc., el número actual de acciones en circulación es 103.13M. Al final de December 2023, la empresa tenía 95.88M acciones en circulación. El número de acciones en circulación generalmente se ve afectado por divisiones de acciones y recompras.
Historial de acciones en circulación de Intra-Cellular Therapies, Inc. (ITCI) desde 2013 hasta 2026
Acciones en circulación al final de cada año
| Año | Acciones en circulación | Cambiar |
|---|---|---|
| 2026 (TTM) | 103.13M | 0.00% |
| 2024 | 103.13M | 7.56% |
| 2023 | 95.88M | 1.95% |
| 2022 | 94.05M | 15.74% |
| 2021 | 81.25M | 15.47% |
| 2020 | 70.36M | 27.50% |
| 2019 | 55.19M | 0.87% |
| 2018 | 54.71M | 18.46% |
| 2017 | 46.18M | 6.80% |
| 2016 | 43.24M | 20.07% |
| 2015 | 36.01M | 25.69% |
| 2014 | 28.65M | 66.35% |
| 2013 | 17.22M | 0.00% |
Acciones en circulación de empresas similares o competidores
| Empresa | Acciones en circulación | Diferencia | País |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 2.40B | 2,226.49% |
IN
|
